HC Wainwright Reaffirms “Buy” Rating for ANI Pharmaceuticals (NASDAQ:ANIP)

HC Wainwright restated their buy rating on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a research report report published on Monday morning,Benzinga reports. HC Wainwright currently has a $94.00 price objective on the specialty pharmaceutical company’s stock.

Several other analysts also recently weighed in on ANIP. StockNews.com upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, March 14th. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Jefferies Financial Group started coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They issued a “buy” rating and a $80.00 target price for the company. Leerink Partners started coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price target on the stock. Finally, Guggenheim lifted their price objective on ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $79.75.

ANI Pharmaceuticals Stock Up 1.0 %

ANIP stock opened at $64.87 on Monday. The firm has a market cap of $1.41 billion, a PE ratio of -117.95 and a beta of 0.63. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The firm’s 50 day moving average price is $59.00 and its 200-day moving average price is $58.12. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $70.81.

Insider Activity at ANI Pharmaceuticals

In related news, SVP Krista Davis sold 1,000 shares of the stock in a transaction on Friday, February 21st. The shares were sold at an average price of $60.20, for a total value of $60,200.00. Following the transaction, the senior vice president now directly owns 68,624 shares of the company’s stock, valued at $4,131,164.80. This trade represents a 1.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the sale, the vice president now owns 80,545 shares in the company, valued at $5,100,914.85. This represents a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,200 shares of company stock valued at $191,776 over the last three months. 12.70% of the stock is owned by corporate insiders.

Institutional Trading of ANI Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of ANIP. Principal Financial Group Inc. raised its position in ANI Pharmaceuticals by 6.9% in the 3rd quarter. Principal Financial Group Inc. now owns 89,961 shares of the specialty pharmaceutical company’s stock valued at $5,367,000 after purchasing an additional 5,829 shares during the last quarter. Victory Capital Management Inc. raised its position in ANI Pharmaceuticals by 153.6% in the 3rd quarter. Victory Capital Management Inc. now owns 12,919 shares of the specialty pharmaceutical company’s stock valued at $771,000 after purchasing an additional 7,825 shares during the last quarter. Natixis Advisors LLC raised its position in ANI Pharmaceuticals by 56.2% in the 3rd quarter. Natixis Advisors LLC now owns 18,184 shares of the specialty pharmaceutical company’s stock valued at $1,085,000 after purchasing an additional 6,545 shares during the last quarter. Thrivent Financial for Lutherans raised its position in ANI Pharmaceuticals by 2.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock valued at $777,000 after purchasing an additional 299 shares during the last quarter. Finally, Quest Partners LLC raised its position in ANI Pharmaceuticals by 141.1% in the 3rd quarter. Quest Partners LLC now owns 9,893 shares of the specialty pharmaceutical company’s stock valued at $590,000 after purchasing an additional 5,789 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.